BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015;20:6068-6092. [PMID: 25856059 DOI: 10.3390/molecules20046068] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Huang JG, Lim SYS, Aw MM, Quak SH. Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort. Helicobacter 2021;:e12868. [PMID: 34958710 DOI: 10.1111/hel.12868] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Uthansingh K, Kumari R, Pati GK, Behera MK, Sahu MC, Narayan J, Patnaik SK, Mallick P, Sahu MK. Molecular Docking of Anti Helicobacter pylori Antibiotics and Proton Pump Inhibitor: A Single Center Survey. J Pure Appl Microbiol 2021;15:2103-2116. [DOI: 10.22207/jpam.15.4.33] [Reference Citation Analysis]
3 Seyedmajidi MR, Hosseini SA, Vafaeimanesh J. Comparing the Effect of Two Low-dose and High-dose Four-drug Regimens of Furazolidone in Eradicating Helicobacter Pylori. Middle East J Dig Dis 2021;13:131-8. [PMID: 34712451 DOI: 10.34172/mejdd.2021.216] [Reference Citation Analysis]
4 Miftahussurur M, Waskito LA, Fauzia KA, Mahmudah I, Doohan D, Adnyana IK, Khomsan A, Ratnasari N, Rezkitha YAA. Overview of Helicobacter pylori Infection in Indonesia: What Distinguishes It from Countries with High Gastric Cancer Incidence? Gut Liver 2021;15:653-65. [PMID: 32616679 DOI: 10.5009/gnl20019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fu J, Sun CF, He HY, Ojha SC, Shi H, Deng CL, Sheng YJ. The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis. Pharmacogenomics 2021;22:859-79. [PMID: 34414773 DOI: 10.2217/pgs-2020-0127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Watanabe T. Synthesis and Structure−Activity Relationship Study of Intervenolin, an Antitumor and Anti-Helicobacter pylori Quinolone Natural Product. HETEROCYCLES 2021;102:1894. [DOI: 10.3987/rev-21-957] [Reference Citation Analysis]
7 Alkhamiss AS. Evaluation of Better Staining Method among Hematoxylin and Eosin, Giemsa and Periodic Acid Schiff-Alcian Blue for the Detection of Helicobacter pylori in Gastric Biopsies. Malays J Med Sci 2020;27:53-61. [PMID: 33154702 DOI: 10.21315/mjms2020.27.5.6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ye L, Meng F, Mao X, Zhang Y, Wang J, Liu Y, Zhu W, Gu B, Huang Q. Using next-generation sequencing to analyze Helicobacter pylori clones with different levofloxacin resistances from a patient with eradication failure. Medicine (Baltimore) 2020;99:e20761. [PMID: 32769862 DOI: 10.1097/MD.0000000000020761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Mahant S, Sharma AK, Gehlot V, Mukhopadhyay AK, Chhawchharia A, Dutta S, Agarwal A, Som A, Das K, Das R. Geographically distinct North-East Indian Helicobacter pylori strains are highly sensitive to clarithromycin but are levofloxacin resistant. Indian J Med Microbiol 2019;37:337-44. [PMID: 32003330 DOI: 10.4103/ijmm.IJMM_19_158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Nguyễn TÁ. Nhân một trường hợp bệnh Malt lymphoma dạ dày. jcmhch 2020. [DOI: 10.38103/jcmhch.2020.59.13] [Reference Citation Analysis]
12 Bayati S, Alebouyeh M, Amirmozafari N, Ebrahimi Daryani N, Talebi M, Zali MR. Histological changes in refractory Helicobacter pylori infection and its relationship with increased levels of resistance to antibiotics and therapeutic regimens: one-year follow-up. APMIS 2020;128:25-34. [PMID: 31628820 DOI: 10.1111/apm.13001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Byambajav TO, Bira N, Choijamts G, Davaadorj D, Gantuya B, Sarantuya T, Sarantuya G, Enkhtsetseg A, Erdenetsogt D, Battulga A, Tserentogtokh T, Matsuhisa T, Yamaoka Y, Oyuntsetseg K. Initial Trials With Susceptibility-Based and Empiric Anti-H. pylori Therapies in Mongolia. Front Pharmacol 2019;10:394. [PMID: 31040783 DOI: 10.3389/fphar.2019.00394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
14 Chakravarty K, Gaur S. Role of Probiotics in Prophylaxis of Helicobacter pylori Infection. CPB 2019;20:137-45. [DOI: 10.2174/1389201020666190227203107] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
15 Arévalo Galvis A, Trespalacios Rangel AA, Otero Regino W. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy. Helicobacter 2019;24:e12574. [PMID: 30859680 DOI: 10.1111/hel.12574] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
16 Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Siregar G, Richardo M, Bakry AF, Rezkitha YAA, Wibawa IDN, Yamaoka Y. Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance. Infect Drug Resist. 2019;12:345-358. [PMID: 30774400 DOI: 10.2147/idr.s187063] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
17 Aslanova KR. SOME RESULTS AND PROSPECTS OF THE STUDY OF HELICOBACTER PYLORI INFECTION. VPBM 2019;1:111. [DOI: 10.29254/2077-4214-2019-1-2-149-111-114] [Reference Citation Analysis]
18 Pasala C, Chilamakuri CSR, Katari SK, Nalamolu RM, Bitla AR, Umamaheswari A. An in silico study: Novel targets for potential drug and vaccine design against drug resistant H. pylori. Microbial Pathogenesis 2018;122:156-61. [DOI: 10.1016/j.micpath.2018.05.037] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
19 Ohishi T, Masuda T, Abe H, Hayashi C, Adachi H, Ohba SI, Igarashi M, Watanabe T, Mimuro H, Amalia E, Inaoka DK, Mochizuki K, Kita K, Shibasaki M, Kawada M. Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection. Helicobacter 2018;23:e12470. [PMID: 29488678 DOI: 10.1111/hel.12470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
20 Damasceno JPL, Rodrigues RP, Gonçalves RCR, Kitagawa RR. Anti-Helicobacter pylori Activity of Isocoumarin Paepalantine: Morphological and Molecular Docking Analysis. Molecules 2017;22:E786. [PMID: 28498343 DOI: 10.3390/molecules22050786] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
21 Miftahussurur M, Cruz M, Subsomwong P, Jiménez Abreu JA, Hosking C, Nagashima H, Akada J, Yamaoka Y. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg 2017;96:1050-9. [PMID: 28193745 DOI: 10.4269/ajtmh.16-0729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
22 Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6-30. [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288] [Cited by in Crossref: 1565] [Cited by in F6Publishing: 1657] [Article Influence: 313.0] [Reference Citation Analysis]
23 Miftahussurur M, Syam AF, Nusi IA, Makmun D, Waskito LA, Zein LH, Akil F, Uwan WB, Simanjuntak D, Wibawa ID, Waleleng JB, Saudale AM, Yusuf F, Mustika S, Adi P, Maimunah U, Maulahela H, Rezkitha YA, Subsomwong P, Nasronudin, Rahardjo D, Suzuki R, Akada J, Yamaoka Y. Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations. PLoS One. 2016;11:e0166199. [PMID: 27906990 DOI: 10.1371/journal.pone.0166199] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
24 Miftahussurur M, Shrestha PK, Subsomwong P, Sharma RP, Yamaoka Y. Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal. BMC Microbiol. 2016;16:256. [PMID: 27809767 DOI: 10.1186/s12866-016-0873-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
25 Caliskan R, Tokman HB, Erzin Y, Saribas S, Yuksel P, Bolek BK, Sevuk EO, Demirci M, Yılmazli O, Akgul O, Kalayci F, Cakan H, Salih B, Bal K, Kocazeybek B. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015;48:278-84. [PMID: 26108005 DOI: 10.1590/0037-8682-0027-2015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
26 Kocazeybek B, Tokman HB. Prevalence of Primary Antimicrobial Resistance of H. pylori in Turkey: A Systematic Review. Helicobacter. 2016;21:251-260. [PMID: 26395982 DOI: 10.1111/hel.12272] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
27 Asano N, Iijima K, Koike T, Imatani A, Shimosegawa T. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review. World J Gastroenterol 2015; 21(26): 8014-8020 [PMID: 26185372 DOI: 10.3748/wjg.v21.i26.8014] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]